AZN3 Oct 2012 19:53
Panmure Gordon downgraded its stance on AstraZeneca (AZN) from "buy" to "hold" with a reduced target price of 3,000p, from 3,100p. The pharmaceutical giant announced that it has suspended its share buy-back programme, which the broker believes heralds the announcement of an acquisition. However, Panmure said that any purchase would most likely be dilutive. The broker added that there may be further management changes on the way, increasing investment risk. The shares inched up by 14.5p to 2,908p.